Articles dans des revues avec comité de lecture (167)
  1. 20. Krayem, M., Sabbah, M., Najem, A., Wouters, A., Lardon, F., Simon, S., Sales, F., Journé, F., Awada, A., Ghanem, G. E., & Van Gestel, D. (2019). The benefit of reactivating p53 under MAPK inhibition on the efficacy of radiotherapy in melanoma. Cancers (Basel), 11(8), 1093. doi:10.3390/cancers11081093
  2. 21. Soumoy, L., Kindt, N., Ghanem, G. E., Saussez, S., & Journé, F. (2019). Role of macrophage migration inhibitory factor (Mif) in melanoma. Cancers (Basel), 11(4), 529. doi:10.3390/cancers11040529
  3. 22. Krayem, M., Najem, A., Journé, F., Morandini, R., Sales, F., Awada, A., & Ghanem, G. E. (2018). Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget, 9(61), 31888-31903. doi:10.18632/oncotarget.25879
  4. 23. Perdrix, A., Najem, A., Saussez, S., Awada, A., Journé, F., Ghanem, G. E., & Krayem, M. (2017). PRIMA-1 and PRIMA-1Met (APR-246): From mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies. Cancers (Basel), 9(12), 172. doi:10.3390/cancers9120172
  5. 24. Kindt, N., Journé, F., Ghanem, G. E., & Saussez, S. (2017). Galectins and carcinogenesis: Their role in head and neck carcinomas and thyroid carcinomas. International journal of molecular sciences, 18(12), 2745. doi:10.3390/ijms18122745
  6. 25. Najem, A., Krayem, M., Perdrix, A., Kerger, J., Awada, A., Journé, F., & Ghanem, G. E. (2017). New drug combination strategies in melanoma: Current status and future directions. Anticancer research, 37(11), 5941-5953. doi:10.21873/anticanres.12041
  7. 26. Gilot, D., Migault, M., Bachelot, L., Journé, F., Rogiers, A., Donnou-Fournet, E., Mogha, A., Mouchet, N., Pinel-Marie, M. L., Mari, B., Montier, T., Correia, S., Gautron, A., Rambow, F., El Hajj, P., Ben Jouira, R., Tartare-Deckert, S., Marine, J.-C., Felden, B., Ghanem, G. E., & Galibert, M. D. (2017). A non-coding function of TYRP1 mRNA promotes melanoma growth. Nature cell biology, 19(11), 1348-1357. doi:10.1038/ncb3623
  8. 27. Zhang, Y., Guo, J., Yang, W., Goncalves, C., Rzymski, T., Dreas, A., Zyłkiewicz, E., Mikulski, M., Brzózka, K., Golas, A., Kong, Y., Ma, M., Huang, F., Huor, B., Guo, Q., Da Silva, S. D., Rivera-Torres, J., Cai, Y., Topisirovic, I., Su, J., Bijian, K., Alaoui-Jamali, M. A., Huang, S., Journé, F., Ghanem, G. E., Miller, W. W., & Del Rincón, S. S. (2017). MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. The Journal of clinical investigation, 127(11), 4179-4192. doi:10.1172/JCI91258
  9. 28. Najem, A., Krayem, M., Sales, F., Hussein, N., Badran, B., Robert, C., Awada, A., Journé, F., & Ghanem, G. E. (2017). P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. European journal of cancer, 83, 154-165. doi:10.1016/j.ejca.2017.06.033
  10. 29. Wimana, Z., Ghanem, G. E., Gebhart, G., Guiot, T., Vanderlinden, B., Larsimont, D., Doumont, G., Van Simaeys, G., Goldman, S., & Flamen, P. (2017). N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging. Oncotarget, 8(34), 56185-56198. doi:10.18632/oncotarget.17015
  11. 30. van Kempen, L., Redpath, M., Elchebly, M., Klein, K. O., Papadakis, A. A., Wilmott, J. J., Scolyer, R. R., Edqvist, P. H., Pontén, F., Schadendorf, D., Van Rijk, A. A., Michiels, S., Dumay, A., Helbling-Leclerc, A., Dessen, P., Wouters, J., Stass, M., Greenwood, C. M. T., Ghanem, G. E., van den Oord, J., Feunteun, J., & Spatz, A. (2016). The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Science Translational Medicine, 8(369), 369ra177. doi:10.1126/scitranslmed.aai9188
  12. 31. Vlková, K., Réda, J., Ondruŝová, L., Krayem, M., Ghanem, G. E., & Vachtenheim, J. (2016). GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax. International journal of oncology, 49(3), 953-960. doi:10.3892/ijo.2016.3596
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Suivant >>